# Chronic Obstructive Pulmonary Disease (COPD) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/chronic-obstructive-pulmonary-disease-copd

> 8 upcoming FDA catalysts in chronic Obstructive Pulmonary Disease (COPD): AZD6793 (AZN) on Aug to Nov 2027 (topline data readout); AZD6793 (AZN) on August 2027 (primary completion); tozorakimab dose regimen 1 (AZN) on Dec 2028 to Mar 2029 (topline data readout); tozorakimab dose regimen 1 (AZN) on December 2028 (primary completion); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 19, 2026 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | completed | "NCT05158387 (Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-19 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05158387)) |
| January 19, 2026 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | completed | "NCT05166889 (Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-19 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05166889)) |
| February 26, 2026 | [Tozorakimab 1 primary completion](https://sec-api.dev/pdufa/tozorakimab-1) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | completed | "NCT05742802 (Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-26 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05742802)) |
| March 6, 2026 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | completed | "NCT06040086 (Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-06 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06040086)) |
| April 21, 2026 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | completed | "NCT06897748 (A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-21 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06897748)) |
| Aug to Nov 2027 | [AZD6793 topline data readout](https://sec-api.dev/pdufa/azd6793) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | scheduled | "NCT07082738 (A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07082738)) |
| August 2027 | [AZD6793 primary completion](https://sec-api.dev/pdufa/azd6793) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | scheduled | "NCT07082738 (A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07082738)) |
| Dec 2028 to Mar 2029 | [Tozorakimab dose regimen 1 topline data readout](https://sec-api.dev/pdufa/tozorakimab-dose-regimen-1) | AZN | Chronic Obstructive Pulmonary Disease; COPD | scheduled | "NCT07566195 (Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07566195)) |
| December 2028 | [Tozorakimab dose regimen 1 primary completion](https://sec-api.dev/pdufa/tozorakimab-dose-regimen-1) | AZN | Chronic Obstructive Pulmonary Disease; COPD | scheduled | "NCT07566195 (Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-29 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07566195)) |
| Mar to Jun 2029 | [TEZSPIRE® (tezepelumab) topline data readout](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | scheduled | "NCT06878261 (A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06878261)) |
| Mar to Jun 2029 | [TEZSPIRE® (tezepelumab) topline data readout](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | scheduled | "NCT06883305 (A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06883305)) |
| March 2029 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | scheduled | "NCT06878261 (A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06878261)) |
| March 2029 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | scheduled | "NCT06883305 (A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-13 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06883305)) |

## Drugs

- [Tozorakimab](https://sec-api.dev/pdufa/tozorakimab) (AZN)
- [Tozorakimab 1](https://sec-api.dev/pdufa/tozorakimab-1) (AZN)
- [AZD6793](https://sec-api.dev/pdufa/azd6793) (AZN)
- [Tozorakimab dose regimen 1](https://sec-api.dev/pdufa/tozorakimab-dose-regimen-1) (AZN)
- [TEZSPIRE® (tezepelumab)](https://sec-api.dev/pdufa/tezepelumab) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/chronic-obstructive-pulmonary-disease-copd.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Chronic Obstructive Pulmonary Disease (COPD) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/chronic-obstructive-pulmonary-disease-copd

```bibtex
@misc{secapidev_indications_chronic_obstructive_pulmonary_disease_copd_20261116,
  title        = {Chronic Obstructive Pulmonary Disease (COPD) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/chronic-obstructive-pulmonary-disease-copd}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_chronic_obstructive_pulmonary_disease_copd_20261116","title":"Chronic Obstructive Pulmonary Disease (COPD) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/chronic-obstructive-pulmonary-disease-copd","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
